The Science of Marijuana

The Science of Marijuana

Volumn , Issue , 2010, Pages 1-290

  Iversen, Leslie L ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Attitudes to cannabis; Cannabis receptors; Cannabis research; Cannabis risks; Medical use of cannabis; Naturally occurring cannabis; Recreational use of cannabis

Indexed keywords

EID: 0004036384     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1093/acprof:oso/9780195328240.001.0001     Document Type: Book

References (289)

1. Abel EL. Marihuana. The First Twelve Thousand Years. New York: Plenum Press; 1943 (reprinted 1980).
2. Abood ME. Molecular biology of cannabinoid receptors. Handh Exp Pharmacol. 2005; 168:81-116.
3. Abood ME and Martin BR. Neurobiology of marijuana abuse. Trends Pharmacol Science. 2002; 13:201-206.
4. Abrams DI, Jay CA, Vizoso H, et al. Cannabis in HIV-associated sensory neuropathy. Neurology. 2005; 68:515-521.
5. Adams IB, Martin BR. Cannabis: pharmacology and toxicology in animals and humans. Addiction. 1996; 91:1585-1614.
6. Adams R. Marihuana. Harvey Lect. 1941-1942;37:168-197.
7. Advisory Committee on Drug Dependence. Cannabis. London: Her Majesty's Stationery Office; 1969.
8. Advisory Council on the Misuse of Drugs. Further Consideration of Classification of Cannabis under the Misuse of Drugs Act 1971. London:Home Office; 2005.
9. Advisory Council on the Misuse of Drugs. Pathways to Problems. London:Home Office; 2006.
10. Agurell S, Halldin M, Lindgren J-E, et al. Pharmacokinetics and metabolism of Δ1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev. 1986; 38:21-38.
11. Alger BA. Endocannabinoids: getting the message across. Proc Nat Acad Sci USA. 2004; 101:8512-8513.
12. American Medical Association. Report of the Council on Scientific Affairs to AMA House of Delegates on Medical Marijuana. CSA Report 1-97; 1997.
13. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 4th ed. Washington D.C.: American Psychiatric Association; 1994.
14. Andreasson S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet. 1987; ii:1483-1485.
15. Andreasson S, Allebeck P, Rydberg U. Schizophrenia in users and nonnsers of cannabis. Acta Psychiatr Scand. 1989; 79:505-510.
16. Anslinger H, Cooper CR. Marihuana: assassin of youth. American Magazine. 1937;July:150.
17. Arevola-Martin A, Vela JM, Molina-Holgado E, Borrell J, Guaza C. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J Neurosci. 2003; 23:2511-2516.
18. Armentano P.. Emerging clinical applications for cannabis and cannabinoids. A review of the recent scientific literature, 2000-2006. National Organization for the Reform of Marijuana Laws. Available at:http://www.norml.org; 2006.
19. Arseneault L, Cannon M, Witton J, Murray RM. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry. 2004; 184:110-117.
20. Atha MJ. Cannabinoids and multiple sclerosis. Independent Drug Monitoring Unit. Available at: http://www.idmu.co.uk/canmsreview.htm; 2005.
21. Axelrod J, Eelder C. Cannabinoid receptors and their endogenous agonist anan-damide. Neurochemical Res. 1998; 23:575-581.
22. Baddeley A. The fractionation of working memory. Proc Natl Acad Sci USA. 1996; 93:13468-13472.
23. Baker D, Pryce G, Croxford JL, et al. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. 2001; 15:300-302.
24. Baker D, Pryce G, Davies WL, Hiley CR. In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol Sci. 2006; 27:1-4.
25. Bari M, Battista N, Gezza E, et al. New insights into endocannabinoid degradation and its therapeutic potential. Mini Rev Med Chem. 2006; 6:257-268.
26. Barnes MP. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert Opin Pharmacother. 2006; 7:607-615.
27. Beal JE, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage. 1995; 10:89-97.
28. Bedard M, Dubois, S, Weaver, B. The impact of cannabis on driving. Can J Public Health. 2007; 98: 6-11.
29. Bell R, Wechsler, H, Johnston, LD. Correlates of college student marijuana use: results of a US National Survey. Addiction. 1997; 92: 571-581.
30. Bellochio L, Mancini, G, Vicennati, V, et al. Cannabinoid receptors as therapeutic targets for obesity and metabolic diseases. Curr Opin Pharmacol. 2006; 6: 586-591.
31. Beltramo M, Stella N, Calignano, A, et al. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science. 1997;277:1094-1097.
32. Berke J, Hernton, C.. The Cannabis Experience. Aylesbury, UK: Hazell Watson & Viney. London: Quartet books Ltd; 1974 (reprinted 1977).
33. Berman J, Symonds, C, Birch, R.. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion:results of a randomised controlled trial. Pain. 2004; 112:299-306.
34. Bertolini A, Ferrari, A, Ottani, A, et al. Paracetamol: new vista of an old drug. CNS Drug Rev. 2006; 12:250-275.
35. Bisogno T, Cascio, MG, Saha, B, et al. Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. Biochim Biophys Acta. 2006; 1761:205-212.
36. Blake DR Robson P Ho M, Robson, P, Ho, M, et al. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology. 2006; 45:50-52.
37. Block RI, O'Leary, DS, Ehrhardt, JC, et al. Effects of frequent marijuana use on brain tissue volume and composition. Neuroreport. 2000; 11:491-496.
38. Bonnie RJ, Whitbread, CH. The Marihuana Conviction. A History of Marihuana Prohibition in the Unites States. Charlottesville, VA: University Press of Virginia; 1974.
39. Booth M.. Cannabis: A History. London: Transworld Publishers; 2003.
40. Bortolato M, Campolongo P, Mangieri RA, et al. Anxiolytic-like properties of the anandamide transport inhibitor AM404. Neuropsychopharmacology. 2006; 31:2652-2659.
41. Bowman M and Pihl RO. Cannabis: psychological effects of chronic heavy use. A controlled study of intellectual functioning in chronic users of high potency. Psychopharmacologia. 1973; 29:159-170.
42. Brady CM, DasGupta R, Dalton C, et al. An open-label pilot study of cannabisbased extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler. 2004; 10:425-433.
43. Braude MC. Toxicology of cannabinoids. In: Paton WM, Crown J (eds). Cannabis and Its Derivatives. Oxford: Oxford University Press; 1972:89-99.
44. British Medical Association. Therapeutic Uses of Cannabis. UK Harwood Academic Publishers Amsterdam; 1997.
45. Budney AJ, Hughes JR, Moore BA, Novy PL. Marijuana abstinence effects in marijuana smokers maintained in their home environment. Arch Gen Psychiatry. 2001; 58:917-924.
46. Cabral CA, Staab A. Effects on the immune system. Handb Exp Pharmacol. 2005; 168:386-423.
47. Campbell EA, Tramer MR, Carroll D, et al. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ, 2001; 323:13-16.
48. Canadian Government Commission of Inquiry into the Non-Medical Use of Drugs. Cannabis. Ottawa: Information Canada; 1970.
49. Carai M, Colombo G, Maccioni P, Gessa GL. Efficacy of rimonabant and other cannabinoid CB-1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data. CNS Drug Rev. 2006; 12:91-99.
50. Caspi A, Moffitt TE, Cannon M, et al. Moderation of the effect of adolescentonset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyl transferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry. 2005; 57:1117-1127.
51. Castle DJ, Murray R, (eds). Marijuana and Madness. Cambridge: Cambridge University Press; 2004.
52. Centonze D, Finazzi-Agro A, Bernardi G, Maccarrone M. The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends Pharmacol Sci. 2007; 28:180-187.
53. Chan GCK, Hinds TR, Impey S, Storm DR. Hippocampal neurotoxicity of 9-tetrahydrocannabinol. J Neurosci. 1998; 18:5322-5332.
54. Chan PC, Sills RC, Braun AG, Haseman JK, Bucher JR. Toxicity and carcinogenicity of delta-9-tetrahydrocannabinol in Fischer rats and B6C3F1 mice. Fundament Appl Toxicol. 1996; 30:109-117.
55. Chopra IC, Chopra RN. The use of cannabis drugs in India. Bull Narc. 1957;Jan:4-29.
56. Clarke RC. Marijuana Botany. Berkeley, CA: Ronin Publishing; 1981.
57. Comitas L. Cannabis and work in Jamaica: a refutation of the amotivational syndrome. Ann NY Acad Sci. 1976; 282:24-32.
58. Consroe PF, Snider R. Therapeutic potential of cannabinoids in neurological disorders. In: Mechoulam R (ed). Cannabinoids as Therapeutic Agents. Boca Raton, FL:CRC Press; 1986:21-49.
59. Costa B, Sinicalco D, Trovata AE, et al. AM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine and apoptotic pathways in a rat model of neuropathic pain. Br] Pharmacol. 2006; 148:1022-1032.
60. Cravatt BF|, Giang DK, Mayfield SP, et al. Molecular characterization of an enzyme that degrades neuromodulatory fatty acid amides. Nature. 1996; 384:83-87.
61. Cravatt BF, Demarest K, Patricelli MP, et al. Supersensitivity to anandamide and enhanced endocannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Nat Acad Sci USA. 2001; 98:9371-9376.
62. D'Ambra TE, et al. C-attached aminoalkylindoles: potent cannabinoid mimetics. Bioorganic Med Chem Lett. 1996; 6:17-22.
63. De Fonseca FR, Carrera MRA, Navarro M, Koob GF, Weiss F. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science. 1997; 276:2050-2054.
64. Degenhardt L, Hall W, Lynskey M. Testing hypotheses about the relationship between cannabis use and psychosis. Drug Alcohol Depend. 2003; 71:37-48.
65. Denton TF, Earleywine M. Pothead or pot smoker? A taxometric investigation of cannabis dependence. Subst Abuse Treat Prev Policy. 2006; 1:22.
66. Devane WA, Dysarz A, Johnson MR, Melvin LS, Howlett A. Determination and characterization of a cannabinoid receptor in rat brain. Mo/ Pharmacol. 1988;34:605-613.
67. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992; 258:1946-1949.
68. Dickson-Chesterfield AK, Kidd SR, Moore SA, et al. Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors. Cell Mo/ Neurobiol. 2006; 26:405-421.
69. Di Marzo V, De Petrocellis L, Bisogno T. The biosynthesis, fate and pharmacological properties of endocannabinoids. Handb Exp Pharmacol. 2005; 168:147-185.
70. Dixon WE.. The pharmacology of cannabis indica. BMJ. 1899;Nov 11:1354-1357.
71. Doll R, Peto R, Boreham J, Sutherland I. Mortality from cancer in relation to smoking: 50 years observations on British doctors. Br J Cancer. 2005; 92:426-429.
72. Downer EJ, Boland B, Eogarty M, Campbell V. Aq-Tetrahydrocannabinol induces the apoptotic pathway in cultured cortical neurones via activation of the CB 1 receptor. Neuro Report. 2001; 12:3973-3978.
73. D'Souza DC, Perry E, MacDougall L, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology. 2004; 29:1558-1572.
74. Duane Sofia R. Cannabis: structure-activity relationships. In: Iversen LL, Iversen SD, Snyder SH (eds). Handbook of Psychopharmacology. Vol. 12. New York: Plenum Press; 1978:319-371.
75. Earleywine M. Understanding Marijuana. Oxford: Oxford University Press; 2002.
76. El Sohly MA. Suppository formulations effecting bioavailability of delta-9-THC. US Patent 5,508,03, issued April 16, 1996 (divisional application of US Patent 5,389,375).
77. Egertova M, Elphick MR.. Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C-terminal tail of CB,. J Comp Neurol. 2000; 422:159-171.
78. Egertova M, Giang DK, Cravatt BE, Elphick MR. A new perspective on cannabinoid signalling: complementary localisation of fatty acid amide hydrolase and the CB1 receptor in rat brain. Proc R Soc Lond B Biol Sci. 1998; 265:2081-2085.
79. Elphick MR, Egertova M. The neurobiology and evolution of cannabinoid signaling. Phil Trans R Soc Lond. 2001; 356:381-408.
80. Emrich HM, Leweke EM, Schneider U. Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system. Pharmacol Biochem Behav. 1997; 56:8030-8080.
81. Engelsman EL. Dutch policy on the management of drug-related problems. Br J Addict, 1989:84:211-218.
82. Fegley D, Kathuria S, Mercier R, et al. Anandamide transport is independent of fatty acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AMI 172. Proc Nat Acad Sci USA. 2004;101:8756-8761
83. Felder CC, Glass M.. Cannabinoid receptors and their endogenous agonists. Ann Rev Pharmacol Toxicol 1998; 38:179-200.
84. Fergusson DM, Horwood LJ, Ridder FM. Tests of causal linkage between cannabis use and psychotic symptoms. Addiction. 2005; 100:354-366.
85. Fernandez-Ruiz J, Gonzalez S. Cannabinoid control of motor function at the basal ganglia. Handb Exp Pharmacol. 2005; 168:479-508.
86. Fields HL, Meng ID. Watching the pot boil: selective antagonists of the two cannabinoid receptors unveil distinct but synergistic peripheral analgesic activities for endogenous cannabinoids. Nat Med. 1998; 4:1000-1009.
87. Fletcher JM, Page JB, Francis DJ, et al. Cognitive correlates of long-term cannabis use in Costa Rican men. Arch Gen Psychiatry. 1996; 53:1051-1057.
88. Freeman RM, Adekanmi O, Waterfield MR, et al. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). Int Urognynecol J Pelvic Floor Dysfunct. 2006; 17:636-641.
89. French ED, Dillon K, Wu X. Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neuro Report. 1997; 8:649-652.
90. Fried PA. Prenatal exposure to tobacco and marijuana: effects during pregnancy, infancy, and early childhood. Clin Ohstet Gynecol. 1993; 36:319-337.
91. Fried PA, Watkinson B, Gray R. Differential effects on cognitive functioning in 13- to 16-year-olds prenatally exposed to cigarettes and marihuana. Neurotoxicol Teratol. 2003; 25:427-436.
92. Fries JF. Assessing and understanding patient risk. Scand J Rheumatol. 1992;92(Suppl):21-24.
93. Gettman G. Marijuana production in the United States (2006). Bull Cannabis Reform. 2006;December.
94. Ghodse H. When too much caution can be harmful. Addiction. 1996; 91:764-766.
95. Gieringer D, St Laurent J, Goodrich S. Cannabis vaporiser combines efficient delivery of THC without effecting supply of pyrolytic compounds. J. Cannabis Ther. 2004; 4:7-27.
96. Giuffrida A, Parsons LH, Kerr TM, de Fonseca FR, Navarro M, Piomelli D. Dopamine activation of endogenous cannabinoid signalling in dorsal striatum. Nat Neurosci. 1999; 2:358-363.
97. Goode E. The Marijuana Smokers. New York: Basic books Inc; 1970.
98. Gorter RW, Butorac M, Cobian EP, van der Sluis W. Medical use of cannabis in the Netherlands. Neurology. 2005; 64:917-919.
99. Grinspoon L, Bakalar JB. Marihuana, the Forbidden Medicine. New Haven, CT:Yale University Press; 1993 (revised 1997).
100. Guzman M. Effects on cell viability. Handh Exp Pharmacol. 2005; 168:627-642.
101. Guzman M, Duarte MJ, Blazquez C, et al. A pilot clinical study of Delta-9-terahydrocannabinol in patients with recurrent glioblastoma. Br J Cancer. 2006; 95:197-203.
102. Hall W. A cautious case for cannabis depenalization. In: Earleywine M (ed). Pot Politics. Oxford: Oxford University Press; 2007:91-112.
103. Hall W, Solowij N. Long-term cannabis use and mental health. Br J Psychiatry. 1997; 171:107-108.
104. Hall W, Solowij N, Lemon J. The Health and Psychological Consequences of Cannabis Use. Monograph Series No 25, National Drug Strategy. Canberra:Australian Government Publishing Service; 1994.
105. Han CJ, Robinson JK. Cannabinoid modulation of time estimation in the rat. Behav Neurosci. 2001; 115:243-246.
106. Harper JW, Heath RG, Myers WA. Effects of cannabis sativa on ultrastructure of the synapse in monkey brain. J Neurosci Res. 1977; 3:87-93.
107. Hashibe M, Morgenstern H, Cui Y, et al. Marijuana use and the risk of lung and upper aerodigestive tract cancers: results of a population based casecontrol study. Cancer Epidemiol Biomarkers Prev. 2006; 15:1829-1834.
108. Hashibe M, Straif K, Tashkin DP, et al. Epidemiologic review of marijuana use and cancer risk. Alcohol. 2005; 35:265-275.
109. Heath RG, Eitzjarrel AL, Eontana CJ, Carey RE. Cannabis sativa: effects on brain function and ultrastructure in rhesus monkeys. Biol Psychiatry. 1980; 15:657-691.
110. Heishman SJ, Stitzer M, Yinglilng JE. Effects of tetrahydrocannabinol content on marijuana smoking behaviour, subjective reports, and performance. Pharmacol Bwchem Behav. 1989; 34:173-179.
111. Henquet C, Murray R, Linszen D, van Os J. The environment and schizophrenia: the role of cannabis use. Schizophrenia Bull. 2005; 31:608-612.
112. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci. 1991; 11:563-583.
113. Herning RI, Hooker WT, Jones RT. Tetrahydrocannabinol content and differences in marijuana smoking behaviour. Psvchopharmacology. 1986; 90:160-162.
114. Hickman M, Vickerman P, Macleod J, Kirkbride J, Jones PB. Cannabis and schizophrenia: model projections of the impact of the rise in cannabis use on historical and future trends in schizophrenia in England and Wales. Addiction. 2007; 102:597-606.
115. Himmelstein JL.. The strange career of marihuana. Contributions in Political Science, No 94. Westport, CT: Greenwood Press; 1978.
116. Ho WSV, Hillard CJ. Modulators of endocannabinoid enzyme hydrolysis and membrane transport. Handh Exp Pharmacol. 2005; 168:188-207.
117. Hogestatt ED, Jonsson BAG, Ermund A, et al. Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-de-pendent arachidonic acid conjugation in the nervous system. J Biol Chem. 2005; 280:31405-31412.
118. Hohmann AG, Suplita RL, Bolton NM, et al. An endocannabinoid mechanism for stress-induced analgesia. Nature. 2005; 435:1108-1111.
119. Hollister LE. Health Aspects of Cannabis. Pharmacol Rev. 1986; 38:1-20.
120. Hollister LE. Health aspects of cannabis: revisited. Int J Neuropsychopharmacol. 1998; 1:71-80.
121. Horti AG, Fan H, Kuwabara H, et al. 11C-JHU75528: a radiotracer for PET imaging of CB1 cannabinoid receptors. J Nucl Med. 2006; 47:1689-1696.
122. House of Lords, Select Committee on Science and Technology. Cannabis-The Scientific and Medical Evidence. London: The Stationery Office; 1998.
123. Howlett AC. Cannabinoid receptor signalling. Handb Exp Pharmacol. 2005; 168:53-80.
124. Huestis MA. Pharmacokinetics and metabolism of the plant cannabinoids, 9-tetrahydrocannabinol, cannabidiol and cannabinol. Handb Exp Pharmacol. 2005; 168:657-690.
125. Huestis MA, Gorelick DA, Heishman SJ, et al. Blockade of effects of smoked marijuana by the CBl-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry. 2001; 58:322-328.
126. Huestis MA, Sampson AH, Holicky BJ, Henningfield JE, Cone EJ. Characterization of the absorption phase of marijuana smoking. Clin Pharmacol Ther. 1992; 52:31-41.
127. Indian Hemp Drugs Commission. Report. Simla, India: Government Central Printing Office; 1894.
128. Institute of Medicine. Joy JE, Watson Jr J, Benson Jr JA (eds). Marijuana and Medicine. Washington DC: National Academy Press; 1999.
129. Iversen LL. Cannabis and the brain. Brain. 2003; 126:1252-1260.
130. Iversen LL, Chapman V Cannabinoids: a real prospect for pain relief? Curr Opin Pharmacol. 2002;2:50-55.
131. Izzo AA, Capasso F. Marijuana for cholera therapy. Trends Pharmac Sci. 2006; 27:7-8.
132. Jahr GHG. New Homeopathic Pharmacopoeia and Posology or the Preparation of Homeopathic Medicines. Philadelphia: J. Dobson; 1842:137.
133. Johns A. Psychiatric effects of cannabis. Br J Psychiatry. 2001; 178:116-122.
134. Johnson JR, GWCA101 Investigator Group, Potts RL. Cannabis-Based Medicines in the Treatment of Cancer Pain- Preliminary Results [Abstract]. Sydney: IASP; August 21-26, 2005.
135. Kandel DB, Davies M. High school students who use crack and other drugs. Arch Gen Psychiatry?. 1996; 53:71-80.
136. Kaslow RA, Blackwelder WC, Ostrow DG, et al. No evidence for a role of alcohol or other psychoactive drugs in accelerating immunodeficiency in HIV-1-positive individuals. JAMA. 1989; 261:3424-3429.
137. Katona I, Sperlagh B, Sik A, et al. Presynaptically located CB, receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci. 1999; 19:4544-4558.
138. King LA, Carpenties C, Griffiths P. An Overview of Cannabis Potency in Europe. European Monitoring Centre for Drugs and Drug Abuse; 2004.
139. Kolodny RC, Masters WH, Kolodner RM, Toro G. Depression of plasma testosterone levels after chronic intensive marihuana use. New Engl J Med. 1974; 290:872-874.
140. Korf DJ, Wouter M, Benschop A, van Ginkel P. Sterke Wiet. Amsterdam:Rozenburg Publishers; 2004.
141. Kozlowski LT, Wilkinson DA, Skinner W, et al. Comparing tobacco cigarette dependence with other drug dependencies. JAMA. 1989; 261:898-901.
142. Kuster JE, Stevenson JI, Ward SJ, D'Ambra TE, Haycock DA. Aminoalkylindole binding in rat cerebellum: selective displacement by natural and synthetic cannabinoids. J Pharmacol Exp Ther. 1993; 264:1352-1363.
143. Lambert DM, Eowler CJ. The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J Med Chem. 2005; 48:5059-5087.
144. Ledent C, et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CBj receptor knockout mice. Science. 1999; 283:401.
145. Lemberger L. Clinical evaluation of cannabinoids in the treatment of disease. In: Harvey DJ, Paton W, Nahas G (eds). Marihuana '84. Oxford: IRL Press Ltd; 1985:673-680.
146. Levine JD, Gordon NC, Bornstein JC, Eields HL. Role of pain in placebo analgesia. Proc Natl Acad Sci USA. 1979; 76:3528-3531.
147. Levitt M, Eaiman C, Hawks R, Wilson A. Randomized double-blind comparison of delta-9-tetrahydrocannabinol (THC) and marijuana as chemotherapy antiemetics. Proc Amer Soc Clin Oncol. 1984; 3:91.
148. Lewin L. PHANTASTICA. Narcotic and Stimulating Drugs their Use and Abuse. London: Routledge&Kegan Paul; 1931.
149. Lichtman AH, Martin BR. Cannabinoid tolerance and dependence. Handh Exp Pharmacol. 2005; 168:691-717.
150. Ligresti A, Moriello AS, Starowicz K, et al. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther. 2006; 318:1375-1387.
151. Lindsey KP, Glaser ST, Gatley SJ. Imaging of the brain cannabinoid system. Handb Exp Pharmacol. 2005; 168:425-443.
152. Linzen DH, Dingemans PM, Lenoir ME. Cannabis abuse and the course of recent onset schizophrenia disorders. Arch General Psychiatry. 1994; 51:273-279.
153. Liu B-Q et al. Emerging tobacco hazards in China: 1. Retrospective proportional mortality study of one million deaths. BMJ. 1998; 317:1411-1422.
154. Ludlow FH. The Hasheesh Eater: Being Passages from the Life of a Pyathagorean. New York: Harper Bros; 1857.
155. Lupica CR, Riegel AC, Hoffman AF. Marijuana and cannabinoid regulation of brain reward circuits. Br J Pharmacol. 2004; 143:227-234.
156. Maccarrone M, Finazzi-Agrò A. Anandamide hydrolase: a guardian angel of human reproduction? Trends Pharmacol Sci. 2004;25:353-357.
157. Maccarrone M, Wenger T. Effects of cannabinoids on hypothalamic and reproductive function. Handh Exp Pharmacol. 2005; 168:556-571.
158. MacCoun R, Reuter P. Interpreting Dutch cannabis policy: reasoning by analogy in the legalization debate. Science. 1997; 278:47-52.
159. Mackie K. Distribution of cannabinoid receptors in the central and peripheral nervous system. Handh Exp Pharmacol. 2005; 168:300-325.
160. Mackie K. Cannabinoid receptors as therapeutic targets. Ann Rev Pharmacol Toxicol. 2006; 46:101-122.
161. Macleod J, Oakes R, Copello A, et al. Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. Lancet. 2004; 363:1579-1588.
162. Makriyannis A, Rapaka R. The molecular basis of cannabinoid activity. Life Sci. 1990; 47:2173-2184.
163. Marshall CR. The active principle of Indian Hemp: a preliminary communication. Lancet. 1897;i:235-238.
164. Marsicano G, Wotjak CT, Azad SC, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature. 2002; 418:488-489.
165. Martin BR. Characterization of the antinociceptive activity of Δ9-tetrahydrocannabinol in mice. In: Harvey DJ (ed). Marihuana '89. Oxford: IRL Press; 1985:685-692.
166. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990; 346:561-564.
167. Matthew RJ, Wilson WH, Coleman RE, Turkington TG, DeGrado TR. Marijuana intoxication and brain activation in marijuana smokers. Life Sci. 1997; 60:2075-2089.
168. Matthew RJ, Wilson WH, Turkington TG, Coleman RE. Cerebellar activity and disturbed time sense after THC. Brain Res. 1998; 797:183-189.
169. Matthias P, Tashkin DP, Marques-Magallanes JA, et al. Effects of varying marijuana potency on deposition of tar and delta-9-THC in the lung during smoking. Pharmacol Biochem Behav. 1997; 58:1145-1150.
170. Mayor La Guardia's Committee on Marihuana. The Marihuana Problem in the City of New York. Lancaster, PA: J. Cattell Press; 1944.
171. Mechoulam R. Marihuana chemistry. Science. 1970; 168:1159-1163.
172. Mechoulam R, Fride E, Di Marzo V. Kndocannaninoids. Eur J Pharmacol. 1998; 359:1-18.
173. Mechoulam R, Hanu L. A historical overview of chemical research on cannabinoids. Chem Physics Lipids. 2000; 108:1-13.
174. Mehra R, Moore BA, Crothers K, Tetrault J, Fiellin DA. The association between marijuana smoking and lung cancer. Arch Intern Med. 2006; 166:1359-1367.
175. Melges FT, Tinklenberg JR, Hollister LE, Gillespie HK. Marihuana and the temporal span of awareness. Arch Gen Psychiatry. 1971; 24:564-567.
176. Moon JB.Moon JB. Sir William Brooke O'Shaugnessy-the foundations of fluid therapy and the Indian telegraph service. New Engl J Med. 1967; 276:283-284.
177. Moore TH, Zammit S, Lingford-Hughes A et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007; 370:319-328.
178. Morton GJ, Cummings DE, Baskin DG, et al. Central nervous system control of food intake and body weight. Nature. 2006; 443:289-295.
179. Nadelmann FA. An end to marijuana prohibition. The drive to legalize picks up. National Review. 2004;July 12.
180. Nagayama T, Sinor AD, Simon RP, et al. Cannabinoids and neuroprotection in global and focal ischemia and in neuronal cultures. J Neurosci. 1999; 19:2987-2995.
181. Nahas G. Keep Off the Grass. New York: Reader's Digest Press; 1976.
182. Nahas G. Marihuana-Deceptive Weed. New York: Raven Press; 1973.
183. Nahas G, Suciv-Foca G, Armand J-P, Morishima A. Inhibition of cellular mediated immunity in marihuana smokers. Science. 1974; 183:419-420.
184. National Commission on Marihuana and Drug Abuse, First Report. Marihuana:A Signal of Misunderstanding, 1972, and Second Report, Drug Use in America: Problem in Perspective, 1973. Washington DC: US Government Printing Office. Available at: http://wvvw.druglibraty.org/schaffer/Library/studies/nc/ncmenu.htm.
185. National Institutes of Health. Report on the Medical Uses of Marijuana. Bethesda, MD: National Institutes of Health; 1997.
186. Navarro M, et al. Acute administration of the CB1 cannabinoid receptor antagonist SR141716A induces anxiety-like response in the rat. Neuro Report. 1997; 8:491-496.
187. Negrete JC, Knapp WP, Douglas DE, Smith WB. Cannabis affects the severity of schizophrenic symptoms: results of a clinical survey. Psychol Med. 1986; 16:515-520.
188. Nurmikko TJ, Serpell MJ, Hoggart B, Toomey PJ, Morlion BJ, Haines D. Sativex successfully treats neuropathic pain characterized by allodynia: a randomized, double-blind, placebo-controlled trial. Pain, 2007 (in press).
189. Okie S. Medical marijuana and the Supreme Court. New Engl J Med. 2005; 353:648-651.
190. Osei-Hyiaman D, DePetrillo M, Pacher P, et al. Endocannabinoid activation of hepatic CB-1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest. 2005; 115:1298-1305.
191. O-Shaugnessey WB. On the preparation of the Indian hemp, or gunjah (cannabis indica) and their effects on the animal system in health and their utility in the treatment of tetanus and other convulsive disorders. Trans Med Phys Soc Calcutta. 1842; 8:421-461.
192. Ossebaard HC. Netherlands- cannabis policy. Lancet. 1996; 347:767-768.
193. Pacher P, Bátkai S, Kunos G. Cardiovascular pharmacology of cannabinoids. Handb Exp Pharmacol. 2005; 168:600-625.
194. Paria BC, Dey SK. Ligand-receptor signalling with endocannabinoids in preimplantation embryo development and implantation. Chem Phys Lipids. 2000; 108:211-220.
195. Pate DW, Jarvinen K, Urtti A, Mahadevan V, Jarvinen T. Effect of the CB1 receptor antagonist, SR141716A on cannabinoid-induced ocular hypotension in normotensive rabbits. Life Sci. 1998; 63:2181-2188.
196. Pério A, Rimaldi-Carmona M, Maruani J, Barth F, Le fur G, Soubrie P. Central mediation of the cannabinoid cue: activity of a selective CB1 antagonist, SR 141716A. Behav Pharmacol. 1996; 7:65-71.
197. Pert CB, Snyder SH. Opiate receptor demonstration in nervous tissue. Science. 1973; 179:1011-1014.
198. Pertwee RG. Tolerance to and dependence on psychotropic cannabinoids. In:Pratt J (ed). The Biological Basis of Drug Tolerance. London: Academic Press Ltd; 1991:231-265.
199. Pertwee RG. The pharmacology and therapeutic potential of cannabidiol. In: Di Marzo V (ed). Cannabinoids. New York: Kluwer Academic/Plenum Publishers; 2004:32-83.
200. Pertwee RG (ed). Cannabinoids. Handb Exp Pharmacol. 2005a;168:1-770.
201. Pertwee RG. Pharmacological actions of cannabinoids. Handb Exp Pharmacol. 2005b;168:1-52.
202. Pettit DA, Harrison MP, Olsen JM, Spencer RF, Cabral GA. Immunohistochemical localization of the neural cannabinoid receptor in rat brain. J Neurosci Res. 1998; 51:391-402.
203. Peto R. Influence of dose and duration of smoking on lung cancer rates. In:Zaridze DG, Peto R (eds). Tobacco: A Major International Health Hazard. Publication No 74. Lyon, France: International Agency for Research on Cancer; 1986:23-33.
204. Peto R, Lopez AD, Boreham J, Thun M, Heath Jr C, Doll R. Mortality from smoking worldwide. Br Med Bull. 1996; 52:12-21.
205. Pijlman FT, Rigter SM, Hoek J, et al. Strong increase in total delta-THC in cannabis preparations sold in Dutch coffee shops. Addict Biol. 2005; 10:171-180.
206. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci. 2003; 4:873-884.
207. Piomelli D. The endocannabinoid system: a drug discovery perspective. Curr Opin Invest Drugs. 2005; 6:672-679.
208. Piomelli V, Tarzia G, Duranti A, et al. Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev. 2006; 12:21-38.
209. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight obese patients. JAMA. 2006; 295:761-775.
210. Plasse TV, Gorter RW, Krasnow SH, Lane M, Shepard KV, Wadleigh RG. Recent clinical experience with dronabinol. Pharmacol Biochem Behav. 1991; 40:695-700.
211. Polen MR, Sidney S, Tekawa IS, Sadler M, Friedman GD. Health care use by frequent marijuana smokers who do not smoke tobacco. West J Med. 1993; 158:596-601.
212. Police Foundation. Drugs and the Law. London: Police Foundation; 2000.
213. Pope HG, Gruber AJ, Hudson JI, et al. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry. 2001a;58:909-915.
214. Pope HG, Ionescu-Pioggia M, Pope KW. Drug use and life style among college undergraduates: a 30-year longitudinal study. Am J Psychiatry. 2001b;158:1519-21.
215. Porter AC, Saner JM, Knierman MD, et al. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB-1 receptor. J Pharmacol Exp Ther. 2002; 301:1020-1024.
216. Pryce G, Baker D. Emerging properties of cannabinoid medicines in management of multiple sclerosis. Trends Neurosci. 2005; 28:272-276.
217. Randall MC, Kendall DA, O-Sullivan S. The complexities of the cardiovascular actions of cannabinoids. Br J Pharmacol. 2004; 142:20-26.
218. Reinarman C, Cohen PDA, Kaal HL. the limited relevance of drug policy:cannabis in Amsterdam and in San Francisco. Am J Public Health. 2004; 94:836-842.
219. Reynolds JR. On the therapeutic uses and toxic effects of cannabis indica. Lancet. 1890;i:637-638.
220. Riedel G, Davies SN. Cannabinoid function in learning, memory and plasticity. Handh Exp Pharmacol. 2005; 168:445-477.
221. Rinaldi-Carmona M, Barth F, Heauim M, et al. SR141716A, a potent and selective antagonist of the cannabinoid receptor. FEBS Lett. 1994; 350:240-244.
222. Robbe H. Marijuana-s impairing effects on driving are moderate when taken alone but severe when combined with alcohol. Human Psychopharmacol. 1998;13:S70-S78.
223. Robinson R. The Great Book of Hemp. Rochester, VT: Park Street Press; 1996.
224. Robson P. Human studies of cannabinoids and medicinal cannabis. Handh Exp Pharmacol. 2005; 168:719-756.
225. Roffman R, Stephens S, eds. Cannabis Dependence. Its Nature, Consequences and -Treatment. International Research Monographs in Addictions. Cambridge: Cambridge University Press; 2006.
226. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005; 65:812-819.
227. Royal College of Physicians. Cannabis and Cannabis-based Medicines. Available at: http://wvvw.rcplondon.ac.uk; 2005.
228. Rubin V (ed). Cannabis and Culture. The Hague: Mouton Publishers; 1975.
229. Russo E. Cannabis for migraine treatment: the once and future prescription? An historical and scientific review. Pain. 1998; 76:3-8.
230. Russo E. History of cannabis and its preparations in saga, science and sobriquet. Chem Biodiversity. 2007; 4:1614-1648.
231. Sánchez C, Galve-Roperh I, Canova C, et al. Delta-9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEES Lett. 1998; 436:6-10.
232. Sañudo-Peña MC, Tsou K, Walker JM. Motor actions of cannabinoids in the basal ganglia output nuclei. Life Sci. 1999; 65:703-713.
233. Satz P, Fletcher JM, Sutker LS. Neurophysiologic, intellectual and personality correlates of chronic marijuana use in native Costa Ricans. Ann NY Acad Sci. 1976; 282:266-306.
234. Scallet AC. Neurotoxicology of cannabis and THC: a review of chronic exposure studies in animals. Pharmacol Biochem Behav. 1991; 40:671-676.
235. Semple DM, Mcintosh AM, Lawrie SM. Cannabis as risk factor for psychosis:systematic review. J Psychopharmacol. 2005; 19:187-194.
236. Serpell MG, Nurmikko T, Wright S. Long-term treatment of peripheral neuropathic pain with a phytocannabinoid medicine (Sativex). [Abstract] British Pain Society Meeting, Glasgow, March 30-April 1, 2006.
237. Serpell MG, Nurmikko TJ, Hoggart B, Toomey PJ, Morlion BJ. A multi-centre double blind, randomised, placebo-controlled trial of oromucosal cannabis based medicine in the treatment of neuropathic pain characterised by allodynia [Abstract]. UK Pain Society Meeting, Edinburgh, March 8-11, 2005.
238. Shen M, Thayer SA. Cannabinoid receptor agonists protect cultured rat hippocam-pal neurons from excitotoxicity. Mol Pharmacol. 1998; 54:459-462.
239. Sidney S, Beck JE, Tekawa IS, Quesenberry CP, Friedman GD. Marijuana use and mortality. Am J Public Health. 1997; 87:585-590.
240. Smiley A. Marijuana: on road and driving simulator studies. Alcohol Drugs Driving. 1986; 2:121-134.
241. Smith AM, Fried PA, Hogan MJ, Cameron I. Effects of prenatal marijuana on visuospatial working memory: an fMRI study in young adults. Neurotoxicol Teratol. 2006; 28:286-295.
242. Smith FL, Cichewicz D, Martin ZL, Welch SP. The enhancement of morphine antinociception in mice by delta-9-tetrahydrocannabinol. Pharmacol Biochem Behav. 1998; 60:559-566.
243. Smith T, Smith H. Process for preparing cannabine or hemp resin. Pharm J. 1846; 6:171-173.
244. Snyder SH. Uses of Marijuana. New York: Oxford University Press; 1971.
245. Solowij N. Cannabis and Cognitive Functioning. Cambridge: Cambridge University Press; 1998.
246. Steffens S, Vellard NR, Arnaud C, et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature. 2005; 434:782-786.
247. Swift W, Hall W, Teesson M. Cannabis use and dependence among Australian adults: results from the National Survey of Mental Health and Wellbeing. Addiction. 2001; 96:737-748.
248. Szabo B, Schlicker E. Effects of cannabinoids on neurotransmission. Handb Exp Pharmacol. 2005; 168:328-365.
249. Tanda C, Pontieri FE, Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common μ1 opioid receptor mechanism. Science. 1997; 276:2048-2050.
250. Tashkin DP. Smoked marijuana as a cause of lung injury. Monalid Arch Chest Dis. 2005; 63:93-100.
251. Terranova JP, et al. Improvement of memory in rodents by the selective CB1 cannabinoid receptor antaognist, SR141716. Psychopharmacology. 1996; 126:165-172.
252. Thakur GA, Nikas SP, Li C, Makryannis A. Structural requirements for cannabinoid receptor probes. Handb Exp Pharmacol. 2005; 168:209-246.
253. Thirthalli J, Benegal V. Psychosis among substance users. Curr Opin Psychiatry. 2006; 19:239-245.
254. Thomas H. Psychiatric symptoms in cannabis users. Br J Psychiatry. 1993; 163:141-149.
255. Thornicroft G. Cannabis and psychosis. Is there epidemiological evidence for an association? Br J Psychiatry. 1990; 157:25-33.
256. Todd AR. Hashish. Experientia. 1946; 2:55-60.
257. Törbjorn U, Järbe C, Henriksson BG. Discriminative response control produced with hashish, tetrahydrocannabinols, and other drugs. Psychopharmacology. 1974; 40:1-16.
258. Trainer MR, Carroll D, Campbell FA, et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ. 2001; 323:16-21.
259. Valverde O, Karsak M, Ziminer A. Analysis of the endocannabinoid system by using CB1 cannabinoid receptor knockout mice, Handb Exp Pharmacol. 2005;168:117-146.
260. Van Amsterdam JGC, van der Laan JW, Slangen JL. Residual effects of prolonged heavy cannabis use. Report No. 318902003. Bilthoven, Netherlands: National Institute of Public Health and the Environment; 1996.
261. Van Sickle MD, Duncan M, Kingsley PJ, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science. 2005; 310:329-332.
262. Varma N, Carlson GC, Ledent C, Alger BE. Metabotropic glutamate receptors drive the endocannabinoid system in hippocampus. J Neurosci. 2001;21:RC188.
263. Vaughan VW, Christie MJ. Retrograde signalling by endocannabinoids. Handb Exp Pharmacol. 2005; 168:368-383.
264. Wade D, Collin C, Stephens M. Meta-analysis of the effects of sativex on spasticity in MS subjects. JMS Clin Lab Res. 2005;11(Supp 1):S97.
265. Wade DT, Makela PM, House H, Bateman C, Robson P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler. 2006; 12:639-645.
266. Walker JM, Hohmann AG. Cannabinoid mechanisms of pain suppression. Handb Exp Pharmacol. 2005; 168:511-544.
267. Walton RP. Marihuana. Americas New Drug Problem. New York: J.B. Lippincott Co; 1938.
268. Wang H, Dey SK, Maccarrone M. Jekyll and Hyde: two faces of cannabinoid signalling in male and female fertility. Endocrin Rev. 2006; 27:427-448.
269. Warburton H, May T, Hough M. Looking the other way. The impact of reclassifying cannabis on police warnings, arrests and informal action in England and Wales. Br J Criminol. 2005; 45:113-128.
270. Ware MA, Adams H, Guy GW. The medicinal use of cannabis in the UK:results of a nationwide survey. Int J Clin Pract. 2005; 59:291-295.
271. Weil AT, Zinberg NE, Nelsen JM. Clinical and psychological effects of marihuana in man. Science. 1968; 162:1234-1242.
272. WHO. Cannabis: a Health Perspective and Research Agenda. 1997. Geneva, World Health Organization.
273. Wiley JL, Barret RL, Lowe J, Balster RL, Martin BR. Discriminative stimulus effects of CP55, 940 and structurally dissimilar cannabinoids in rats. Neuropharmacology. 1995; 34:669-676.
274. Williams JH, Wellman NA, Rawlins JNP. Cannabis use correlates with schizotypy in healthy people. Addiction. 1996; 91:869-887.
275. Williams SJ, Hartley JPR, Graham JDP. Bronchodilator effects of delta-9-THC administered by aerosol to asthmatic patients. Thorax. 1976; 31:720-723.
276. Wilson RI, Nicoll RA. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature. 2001; 410:588-592.
277. Wisset R. A Treatise on Hemp. London: J. Harding; 1808.
278. Witkin JM, Tzavara ET, Davis RJ, Li X, Nomikos GG. A therapeutic role for cannabinoid CB-1 receptor antagonists in major depressive disorders. Trends Pharmacol Sci. 2005; 26:609-617.
279. Wood GB, Bache E. The Dispensatory of the United States. Philadelphia:Lippincott; 1854:339.
280. Wu TC, Tashkin DP, Djaheb B, Rose JK. Pulmonary hazards of smoking marijuana as compared with tobacco. New Engl J Med. 1988; 31:347-351.
281. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003; 362:1517-1526.
282. Zajicek JP, Sanders HP, Wright DK, et al. Cannabinoids in multiple sclerosis (CAMS study): safety and efficacy data for 12 months follow-up. J Neurol Neurosurg Psychiatry. 2005; 76:1664-1669.
283. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969:historical cohort study. BMJ. 2002; 325:1195-1212.
284. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci USA. 1999; 96:5780-5785.
285. Zimmer L, Morgan JP. Marijuana Myths, Marijuana Facts. New York:Lindesmith Center; 1997.
286. Ziring D, Wei B, Velazquez P, Schrage M, Buckley NF, Braun J. Formation of B and T cell subsets require the cannabinoid receptor CB2. Immune genetics. 2006; 58:714-725.
287. Zuardi AW, Crippa JAS, Hallak JFC, Moreira FA, Guimaraes FS. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res. 2006; 39:421-429.
288. Zuardi AW, Shirakawa I, Finkelfarb F, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by delta-9-THC in normal subjects. Psycho-pharmacology. 1982; 76:245-250.
289. Zuckerman B, Frank DA, Hingson R, et al. Fffects of maternal marijuana and cocaine use on fetal growth. New Engl J Med. 1 989; 320:762-768.